4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
about
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesRecombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).The change of immunoactivity of dendritic cells induced by mouse 4-1BBL recombinant adenovirus.Features of responding T cells in cancer and chronic infection.Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancerEffects of 4-1BB signaling on the biological function of murine dendritic cells.Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer.Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Targeting costimulatory pathways for tumor immunotherapy.On the potential of oncolytic virotherapy for the treatment of canine cancers.Integrating costimulatory agonists to optimize immune-based cancer therapies.OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory virusesOncolytic virus therapy for cancer.Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).Construction of a recombinant adenovirus co-expressing truncated human prostate-specific membrane antigen and mouse 4-1BBL genes and its effect on dendritic cells.
P2860
Q27012963-A9D754F2-5D55-4B60-B522-F49FE53CF8A6Q27314155-DEA3CE7C-AF10-4167-BBC9-D7F347B23250Q33320536-5CF73FE9-509B-4690-BFAB-096A381A3780Q33892286-D1A5D875-A945-4550-93B7-18646CF25C79Q33941340-ED13504C-26ED-44AB-8C17-A2DAD16EB1D1Q35726637-D1775188-DE18-4ED6-8AA9-FF26F7E06BCFQ35995857-A0D06C9E-907A-4198-8609-C7DD0810BE65Q36412657-5D6C9E30-1F6A-42E9-8D3A-AEE7E1A5C09AQ36546669-CD28174A-CDBE-4BCB-8932-74ADECC663CCQ36664213-EAD98B16-121A-443F-AA0E-E2B047E1E2CDQ36844950-E8B11EFB-52D6-4678-9F04-7C5F9D662823Q37031925-62FD2506-2D97-4263-8547-F18F6976755AQ37352989-AC44D417-AC46-4951-AC61-BFC54F0BECC8Q37948126-55FC3600-F371-4F06-A4E5-4AC6C8C0E577Q38924529-9F93D5A0-E87A-4269-8CC8-B83C772A803DQ42089413-71D2D207-99E1-4442-944C-74496EA238D3Q50528363-F9417B02-8278-4FB4-AB9E-7FCD6AA67FC5
P2860
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@ast
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@en
type
label
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@ast
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@en
prefLabel
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@ast
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@en
P2093
P2860
P1433
P1476
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
@en
P2093
Chie Kudo-Saito
Heesun Kwak
Howard L Kaufman
James W Hodge
Jeffrey Schlom
Seunghee Kim-Schulze
P2860
P304
P356
10.1016/J.VACCINE.2006.03.042
P407
P577
2006-03-31T00:00:00Z